# Treat and Extend Analysis Trial With Aflibercept in Wet-AMD

> **NCT04113538** · PHASE3 · UNKNOWN · sponsor: **Michel Giunta** · enrollment: 40 (actual)

## Conditions studied

- Wet Age-related Macular Degeneration

## Interventions

- **DRUG:** Aflibercept

## Key facts

- **NCT ID:** NCT04113538
- **Lead sponsor:** Michel Giunta
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-07-24
- **Primary completion:** 2023-01
- **Final completion:** 2023-05
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-06-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04113538

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04113538, "Treat and Extend Analysis Trial With Aflibercept in Wet-AMD". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04113538. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*